Citation Impact
Citing Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
2015 Standout
FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1
2010
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
2013 Standout
Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression
2017 Standout
Custom Cerium Oxide Nanoparticles Protect against a Free Radical Mediated Autoimmune Degenerative Disease in the Brain
2013
The Blood–Brain Barrier
2015 Standout
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
2012
Neurofilament light chain as a biomarker in neurological disorders
2019 Standout
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 Standout
Sphingolipid metabolism in cancer signalling and therapy
2017
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
2014 StandoutNobel
Sphingolipids and their metabolism in physiology and disease
2017 Standout
Purification and Identification of Activating Enzymes of CS-0777, a Selective Sphingosine 1-Phosphate Receptor 1 Modulator, in Erythrocytes
2011
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
2017
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 StandoutNobel
Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism
2016 Standout
The Human Plasma Lipidome
2011
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
2010
Pediatric Multiple Sclerosis
2011
Diversity and plasticity of microglial cells in psychiatric and neurological disorders
2015
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches
2018 Standout
Sphingolipid signaling in yeast potential implications for understanding disease
2012
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
2015
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
Immunopathology of multiple sclerosis
2015 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Current state of immunotherapy for glioblastoma
2018
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
2013
Ulcerative colitis
2016 Standout
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis
2019
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
2010
How do immune cells overcome the blood–brain barrier in multiple sclerosis?
2011
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
2012 Standout
The Future of Immunotherapy: A 20-Year Perspective
2017
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm
2011
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
2020 Standout
Ulcerative colitis
2020 Standout
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics
2011
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
2019 Standout
Therapies for multiple sclerosis: translational achievements and outstanding needs
2013
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients
2012
The acute respiratory distress syndrome
2012 Standout
Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing
2014 Standout
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
2011
Sphingosine 1-phosphate in coagulation and inflammation
2011
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
2016
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
2018
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
Exosomes
2019 Standout
Bioactive Benzofuran derivatives: A review
2014
Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
2011
The Sphingosine 1-Phosphate Receptor, S1PR1, Plays a Prominent But Not Exclusive Role in Enhancing the Excitability of Sensory Neurons
2010
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
2016
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48
2016
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
2018
Multiple Sclerosis
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
2015
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF
2018
Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics
2015 Standout
Discovery Of Fingolimod, The Sphingosine 1-Phosphate Receptor Modulator And Its Application For The Therapy Of Multiple Sclerosis
2012
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Atacicept: targeting B cells in multiple sclerosis
2010
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite
2011
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
2011
Direct Renin Inhibitors as a New Therapy for Hypertension
2010
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications
2017
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist
2011
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of James Jin being referenced
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
2016
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
2013
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study
2015
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
2008
EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL
2017
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation
2008
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
2018
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
2009